Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
December 16, 2022
In Regard to Dess
Jonathan Tward, Lauren Lenz
The Prostate
|
January 21, 2021
Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone
Gregory P Swanson, Lauren Lenz, Steven Stone, et al.
European Journal of Breast Health
|
April 9, 2026
Cancer Risk Assessment and Hereditary Cancer Genetic Testing in a Community OBGYN Setting
Edith Smith, Logan Schneider, Lauren Lenz, et al.
Journal of Midwifery & Women'S Health
|
April 28, 2026
Optimizing Hereditary Cancer Risk Assessment and Genetic Testing Workflow in Interprofessional Women's Health Practice: A Multicenter Survey of Advanced Practice Providers
Elaine Mielcarski, Dana Karanik, Heather Bagley, et al.
Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology
|
May 13, 2026
Results of breast cancer risk assessment and hereditary cancer genetic testing in community obstetrics and gynaecology practice following a prospective quality Improvement initiative
Richard Waldman, Mark DeFrancesco, John Feltz, et al.
JCO Precision Oncology
|
May 15, 2024
Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer
Jonathan D Tward, Lauren Lenz, Alexander Gutin, et al.
Cancer Reports (Hoboken, N.J.)
|
August 23, 2021
Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy
Jack M Cuzick, Steven Stone, Lauren Lenz, et al.
Urologic Oncology
|
December 1, 2020
Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer
David S Morris, J Scott Woods, Byard Edwards, et al.
Clinical Genitourinary Cancer
|
February 20, 2021
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy
Jonathan D Tward, Thorsten Schlomm, Stephen Bardot, et al.
Obstetrics and Gynecology
|
December 5, 2024
Online Screening and Virtual Patient Education for Hereditary Cancer Risk Assessment and Testing
Richard N Waldman, Mark S DeFrancesco, John P Feltz, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
International Journal of Radiation Oncology, Biology, Physics
|
December 16, 2022
In Regard to Dess
Jonathan Tward, Lauren Lenz
The Prostate
|
January 21, 2021
Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone
Gregory P Swanson, Lauren Lenz, Steven Stone, et al.
European Journal of Breast Health
|
April 9, 2026
Cancer Risk Assessment and Hereditary Cancer Genetic Testing in a Community OBGYN Setting
Edith Smith, Logan Schneider, Lauren Lenz, et al.
Journal of Midwifery & Women'S Health
|
April 28, 2026
Optimizing Hereditary Cancer Risk Assessment and Genetic Testing Workflow in Interprofessional Women's Health Practice: A Multicenter Survey of Advanced Practice Providers
Elaine Mielcarski, Dana Karanik, Heather Bagley, et al.
Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology
|
May 13, 2026
Results of breast cancer risk assessment and hereditary cancer genetic testing in community obstetrics and gynaecology practice following a prospective quality Improvement initiative
Richard Waldman, Mark DeFrancesco, John Feltz, et al.
JCO Precision Oncology
|
May 15, 2024
Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer
Jonathan D Tward, Lauren Lenz, Alexander Gutin, et al.
Cancer Reports (Hoboken, N.J.)
|
August 23, 2021
Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy
Jack M Cuzick, Steven Stone, Lauren Lenz, et al.
Urologic Oncology
|
December 1, 2020
Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer
David S Morris, J Scott Woods, Byard Edwards, et al.
Clinical Genitourinary Cancer
|
February 20, 2021
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy
Jonathan D Tward, Thorsten Schlomm, Stephen Bardot, et al.
Obstetrics and Gynecology
|
December 5, 2024
Online Screening and Virtual Patient Education for Hereditary Cancer Risk Assessment and Testing
Richard N Waldman, Mark S DeFrancesco, John P Feltz, et al.
Page
of 2